Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SARC041
— Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SARC041
by Wayne Kuznar, contributing writer
May 31, 2026
• 3 min read
CHICAGO -- Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to the SARC041 trial.
Abemaciclib may be new standard for ‘challenging’ sarcoma subtype
Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology
Akeso, Summit drug extends survival in closely watched lung cancer trial
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer
Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting
